Founded in November 2014, Genecast (Beijing) Biotechnology Co. is located within the Beijing HealthWork Mobile Health Industry Park. With the next-generation sequencing technology and bioinformatics as its core, the company is dedicated to precise noninvasive individualized cancer diagnosis and treatment, and companion diagnosis. It is also determined to become a leader in improving quality of life for cancer patients.
To date, Genecast Biotechnology has established a technology platform for optimized cell-free DNA extraction and quantitative testing. It has the country’s first technology platform for companion diagnostics, prognosis evaluation and medication guidance for multiple solid tumors (lung, colorectal, liver, esophageal, endometrial, ovarian, and cervical cancers) based on cfDNA testing.
State-of-the-art Genecast labs and production base
The Genecast Lab (Phase II) was funded and established in June 2017 by Genecast Biotechnology. The lab is dedicated to cancer-specific molecular biology medical tests, which provide cancer patients and doctors with accurate medical test results relating to cancer, and which enable doctors to make individualized treatment plans.
The Genecast Lab covers more than 600 m2 of floor space and has been constructed in accordance with ISO 15189 and CAP regulations. It is equipped with sophisticated quality-control systems and maintains a complete set of SOP. In addition to standard molecular lab equipment, the lab also houses an llumina Novoseq 6000 sequencing system, a Thermo King Fisher Flex, an automatic nucleic acid extractor, a Hamilton Star automatic platform, an intelligent high-speed refrigerated centrifuge, a gradient PCR instrument, a vacuum centrifugal concentrator, a micro-drop digital PCR system, and an LIMS system. With such advanced equipment at its disposal, the lab capable of producing cancer-related molecule and pathology tests to the highest of clinical standards.
In addition, Genecast Biotechnology also has an independent medical laboratorie: a nearly 2000m2 lab, which meets requirements set by the National Health and Family Planning Commission of the People’s Republic of China for high-throughput sequencing labs; together with a 1900m2 GMP production base for IVD kit manufacturing. An 1800m2 big data center for accurate cancer diagnosis and treatment is also under construction in Wuxi.
Extensive hospital cooperation
Genecast Biotechnology has integrated R&D, production and medical inspection. It has also independently developed multiple national and international patents and software copyright licenses. So far, it has collaborated with many top hospitals, including the Peking University Cancer Hospital, the Chinese Academy of Medical Sciences Cancer Hospital, People’s Liberation Army (PLA) 81 Hospital, and Shanghai Jiao Tong University School of Medicine Ruijin Hospital. Moreover, Genecast Biotechnology has formed partnerships with many life science, biotech and pharma companies around the world to develop IVD and companion diagnostic testing.
Lead by the best
Genecast Biotechnology’s team is made up of leading experts in clinical medicine, bioinformatics and molecular biology. Together, they offer extensive experience in precision medicine and high-throughput sequencing. Globally, Genecast Biotechnology employs more than 500 people. Within its R&D team alone, more than 21% of employees hold PhDs and more than 40% hold master's degrees. The company has also established a nation-wide sales network driven by highly knowledgeable sales teams.